Researchers at Georgetown University Medical Center say they are moving closer to understanding why the most lethal form of human malaria has become resistant to drug treatment in the past three decades.
An easily identifiable dermatologic condition, acanthosis nigricans, is associated with having multiple risk factors for type 2 diabetes, in patients aged 7 to 39 years, finds this study of 1,113 patients.
In an early step toward nonsurgical screening for malignant skin cancers, Duke University chemists have demonstrated a laser-based system that can capture three-dimensional images of the chemical and structural changes under way beneath the surface of human skin.
Bayer HealthCare, a subsidiary of Bayer AG (NYSE: BAY), and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar? (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%.
GlaxoSmithKline (NYSE: GSK) announced that the European Commission approved its novel topical antibacterial ALTARGO? (retapamulin ointment,1%) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds.
Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma.
Two persons have died and four others are battling for their lives after being infected by anthrax in Orissa’s tribal Koraput district, official sources said.
University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease.
Researchers in endocrinology and obstetrics and gynecology at Cedars-Sinai Medical Center will make several presentations at the upcoming annual meetings of two medical organizations ? the Androgen Excess Society (June 1, 2007) and the Endocrine Society (June 2-5, 2007).
Women with breast cancer who receive higher doses of radiation with IMRT each day can reduce their treatment time by two weeks without increasing side effects, according to a study released today in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.